Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 10,963

Document Document Title
WO/2009/132452A8
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of subs...  
WO/2009/091704A3
Fluorine-free photoacid generators and photoresist compositions containing fluorine-free photoacid generators are enabled as alternatives to PFOS/PFAS photoacid generator-containing photoresists. The photoacid generators are characterize...  
WO/2010/006725A1
A compound of formula (I) wherein A1, A2, A3, A4, G1, G2, R1, R2, L, Q1, and Q2 are as defined in claim 1; or a salt or N- oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds o...  
WO/2010/008299A1
The present invention relates to lipid compounds of the general formula (I): (I) wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same...  
WO/2009/132453A8
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of subs...  
WO/2010/003127A2
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists Of PGD2 receptors. Also described here...  
WO/2009/109866A3
This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamid e (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through inter...  
WO/2009/157418A1
Disclosed is a highly safe agent for treating and/or preventing diabetes or the like, which has excellent activity. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (...  
WO/2009/157196A1
Disclosed is a compound having GPR52 agonist activity and serving as an agent for preventing or treating schizophrenia or the like. Specifically disclosed is a compound represented by formula (I) or a salt thereof. In the formula, A repr...  
WO/2009/149806A2
The invention relates to 4-(3-alkyl sulfinyl benzoyl) pyrazoles of the general formula (I) as herbicides. In said formula (I), R1 through R4, X, and Y stand for radicals such as hydrogen, organic radicals such as alkyls, and other radica...  
WO/2009/147632A2
The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza- undecane-2,4,8,10-tetraol.  
WO/2009/145219A1
Disclosed is a means for treating Alzheimer's disease, which utilizes a secretase inhibitor and is highly safe. Specifically disclosed is a compound represented by general formula (I) [wherein A represents a phenyl group or the like; R1...  
WO/2009/144344A2
Compound for labelling biomolecules based on vinylsulphone, preparation and uses, comprising a labelling molecule and a vinylsulphone group. In addition it relates to the use of the compounds as labelling agents, to the procedure of obta...  
WO/2009/140765A1
The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases...  
WO/2009/139438A1
Disclosed is a process for producing an optically active carboxylic acid from a racemic carboxylic acid in a conventional production facility with high efficiency and at low cost. Specifically disclosed is a process for producing an opt...  
WO/2009/132453A1
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of subs...  
WO/2009/132452A1
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of subs...  
WO/2009/132832A2
The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.  
WO/2009/131065A1
Disclosed is a compound useful as a prophylactic agent or a therapeutic agent for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases, gastrointestinal diseases, neoplasm, infectious diseases and others...  
WO/2009/128907A1
Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.  
WO/2009/128521A1
Disclosed are: a compound having an excellent inhibitory activity on cysteine protease; and a pharmaceutical agent for the treatment or prevention of a disease selected from the group consisting of osteoporosis, osteoarthrosis deformans,...  
WO/2009/125606A1
Provided is a compound represented by formula (I) having a PAI-1 inhibiting action. [In formula (I), R1 represents an optionally substituted C6-10 aryl group etc., T represents a single bond etc., m is 0 or 1, when m is 0 G represents -N...  
WO/2009/125861A1
Disclosed are a compound having an outstanding cysteine protease inhibiting action, and medicaments for treating or preventing a disorder selected from a set comprising osteoporosis, osteoarthrosis deformans, rheumatoid arthritis, Paget'...  
WO/2009/123109A1
A photosensitive transparent resin composition which is reduced in the dependence on exposure illuminance and which can stably form patterns excellent in resolution with high retention of film thickness and nearly without scum; color fil...  
WO/2009/118292A1
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by a...  
WO/2009/120783A1
Compositions and uses thereof that inhibit HCV life cycle by inhibiting action of the HCV NS3/4A protease. An embodiment of the invention comprises a compound designated RS-2-19.  
WO/2009/116487A1
Disclosed is a method for producing a sulfone compound represented by formula (1), which comprises a step of obtaining a compound represented by formula (4) by reacting a compound represented by formula (3) with a chlorate or a bromate, ...  
WO/2009/114849A1
Asymmetric cyclopropanation of olefins with diazosulfones.  
WO/2009/113508A1
Disclosed is an acid having a fluorine-containing carbanion structure or a salt having a fluorine-containing carbanion structure, which is represented by general formula (1). By using a photoacid generator for chemically amplified resist...  
WO/2009/109483A1
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2009/106664A1
The invention relates to labelling agents containing a compound with a labelled molecule and a vinyl sulphone group. The invention also relates to the compounds, the method for obtaining same and the uses thereof in the marking of biomol...  
WO/2009/049845A3
Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing...  
WO/2009/025791A3
The invention encompasses processes for obtaining pure armodafinil substantially free of disulfide impurities that is suitable for use on an industrial scale. In particular, a processes for purifying armodafinil from bis(diphenylmethyl)d...  
WO/2008/009815A9
The invention relates to aromatic sulfonates, the preparation thereof, and the use of the same as the salt of an electrolyte. The sulfonates have the formula [Ar-Z- (CF2)nCFRf-SO3 -] p Mp+ (I), wherein Z is a sulfide, sulfinyl or sulfony...  
WO/2009/097684A1
The invention relates to a method for measuring the real temperature of a hot spot in an oil-containing electric apparatus, such as a power transformer. The electric apparatus is operated in predetermined and changeable operating conditi...  
WO/2009/024863A3
Disclosed herein is a convenient, commercially viable and environmentally friendly process for the preparation of Armodafinil. The present invention also provides an improved, commercially viable and industrially advantageous process for...  
WO/2009/096545A1
A diurethane compound R2(SO2)m(CH2)nOCONH-R1-NHCOO(CH2)n(SO2)mR2 is produced by a method in which a diamine compound H2NR1NH2 is reacted with a chloroformate compound ClCOO(CH2)n(SO2)mR2 or by a method in which a diisocyanate compound OC...  
WO/2009/073592A3
The present invention provides fluoroalkyl amines represented by the formula R1-Q-S(O)x-C(H),(CH3)r(CH2)z+(1-1)-NHR and fluoroalkyl isocyanates and isothiocyanates represented by the formula RrQ-S(O)x-C(H)l(CH3)r(CH2)Z+(1-1)-N=C=X1, wher...  
WO/2009/045488A3
The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the inven...  
WO/2009/092713A1
This invention relates to novel N-(2-methyl-phenyl-cyclopentyl)sulphonamide derivatives of formula (I) and salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, R8, p, R9 and R10 are as defined in the description. The invention also relates...  
WO/2009/090663A1
The present invention relates to a novel crystalline polymorph of armodafinil. In another aspect the invention relates to an improved process for preparation of the novel polymorph of armodafinil.  
WO/2009/091704A2
Fluorine-free photoacid generators and photoresist compositions containing fluorine-free photoacid generators are enabled as alternatives to PFOS/PFAS photoacid generator-containing photoresists. The photoacid generators are characterize...  
WO/2009/087981A1
Disclosed is a polymerizable compound which can be obtained by a simpler process. The polymerizable compound is represented by formula (1) or (2). [Rf-{R1-X0-(CO)t-R2-}q]mX1-R3-Z (1) Rf-R1-X2-CO(NH)r-R3-Z (2) In the formulae, Rf represen...  
WO/2008/041140A8
This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositio...  
WO/2009/081789A1
A compound that is useful as an agent in the prevention and treatment of circulatory system, nervous system, metabolic, reproductive system, and gastrointestinal diseases. Formula (I) is a compound represented by the following: [structur...  
WO/2009/049961A3
The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.  
WO/2009/061744A3
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (K...  
WO/2009/078268A1
Disclosed is a gelling agent containing a fluoroalkyl derivative, a small amount of which can gelatinize or solidify various organic solvents. Specifically disclosed is a gelling agent for organic liquids, which contains a fluoroalkyl de...  
WO/2009/010156A3
The invention relates to compounds of formula (I) or the salts thereof, wherein Q is a (hetero)aromatic radical having up to 6 ring atoms, the ring of the heteroaromatic radical comprising 1, 2, 3 or 4 nitrogen atoms or 1 sulphur atom or...  
WO/2009/073592A2
The present invention provides fluoroalkyl amines represented by the formula R1-Q-S(O)x-C(H),(CH3)r(CH2)z+(1-1)-NHR and fluoroalkyl isocyanates and isothiocyanates represented by the formula RrQ-S(O)x-C(H)l(CH3)r(CH2)Z+(1-1)-N=C=X1, wher...  

Matches 501 - 550 out of 10,963